Impel Neuropharma, Inc.

Impel Pharmaceuticals Inc.

University of Washington

Healthpartners Research Foundation

Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh

John D Hoekman

Alan Brunelle

Michael Hite

Joel Relethford

Rodney J Y Ho

Christopher William Fuller

Craig Frederick Kohring

Kelsey H Satterly

Aditya R Das

Inna Dashevsky

Stephen B Shrewsbury

Gregory J Davies

Bhavin Y Gajera

Albert Kenneth Lavin

Christopher Fuller

William Howard Frey, Ii

Jens Pohl

Scott Youmans

Leah R Hansom

Ken Maravilla

William H Frey Ii

Rodney Jy Ho

Scott B Youmans

Rodney JY Ho

Craig Kohring

A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.

Nozzles for nasal drug delivery

Embodiments relate to a single-use device for delivery of medication into a nasal cavity. In an embodiment, the device includes a propellant canister containing a propellant capable of propelling the compound to the nasal cavity. The propellant canister is displaceable between an unactuated position and an actuated position within the device. The device further includes an actuation element with an actuation lever configured to displace the propellant canister from the unactuated position to the actuated position. The device also includes a puncture element positioned to puncture the propellant canister, which causes the release of the propellant from the propellant canister. The device further includes a dose holding chamber containing a unit dose of the compound. The dose holding chamber is positioned such that propellant flows into the dose holding chamber and causes the compound to be propelled from the dose holding chamber to the nasal cavity of the user.

Single-use nasal delivery device

A nasal drug delivery device for delivering a plume derived from a propellant and a drug compound. The drug compound is in an intranasal dosage form in the form of powder, suspension, dispersion, or liquid. The propelled intranasal dosage form is deposited within the upper nasal cavity such as the olfactory region. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing channel where the intranasal dosage form is aerosolized. The aerosolized intranasal dosage form passes through a nozzle thus delivering a plume to the user's upper nasal cavity.

Nasal drug delivery device with detachable nozzle

Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (C) of at least 30 ng/mL, with (b) a mean time to C(T) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.

Intranasal delivery of olanzapine by precision olfactory device

A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.

Nasal drug delivery device

A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.

Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's disease

Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease

A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the in-line nasal delivery device compound and the outlet allows for delivery of the compound.

In-line nasal delivery device

Lipid nanoparticles expressing metal ions and methods for using the compositions for magnetic resonance imaging.

Gadolinium expressed lipid nanoparticles for magnetic resonance imaging

A unit dose container for the containment of an intranasal formulation for use with the POD device.

Medical unit dose container

Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (C) of at least 750 pg/ml, (b) with a mean time to C(T) of DHE of less than 45 minutes, and (c) a mean plasma AUCof DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.

Intranasal delivery of dihydroergotamine by precision olfactory device

Growing community of inventors

Seattle, WA, United States of America

John D Hoekman